TOP TEN perturbations for 1052_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1052_s_at
Selected probe(set): 203973_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1052_s_at (203973_s_at) across 6673 perturbations tested by GENEVESTIGATOR:

CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)

Relative Expression (log2-ratio):6.196089
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-8t28BBZ; post-infusion)
CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; glioblastoma, NOS; primary)

Relative Expression (log2-ratio):-4.961192
Number of Samples:2 / 3
Experimental CNS cancer study 1 (PDX; glioma, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted).
Control CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted).

CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)

Relative Expression (log2-ratio):4.916686
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; post-infusion)
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample

Relative Expression (log2-ratio):-4.849846
Number of Samples:7 / 12
Experimental IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):4.6344423
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

B-ALL study 1 (hyperdiploid) / normal bone marrow sample

Relative Expression (log2-ratio):-4.5622864
Number of Samples:40 / 74
Experimental B-ALL study 1 (hyperdiploid)
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)

Relative Expression (log2-ratio):4.271456
Number of Samples:3 / 3
Experimental CAR T cell study 4 (GFP; post-infusion)
CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (GFP; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.2276344
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

retina pigment epithelium study 1 (adult) / retina pigment epithelium study 1 (fetal)

Relative Expression (log2-ratio):4.112406
Number of Samples:2 / 6
Experimental retina pigment epithelium study 1 (adult)
Postmortem human native retina pigment epithelium samples from adult individuals.
Control retina pigment epithelium study 1 (fetal)
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-4.0558586
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.